Scientific presentation selector

Reduction in circulating tumor DNA in relation to radiographic response and tumor PD-L1 expression in a phase 1 study of fetrastobart vedotin (PDL1V; PF-08046054) in patients with non-small cell lung cancer

Saleh R, Nabell L, Fontana E, Steeghs N, Kotecki N, Sàbat P, Dowlati A, Zivi A, Ochsenreither S, Le Tourneau C, Oberoi A, Ouali K, Spreafico A, Gillison M, Guo Y, Yao J, Itani F, Gupta S, Zhang R, Minchom A

Adjusted Ideal Body Weight Dosing Reduces Pharmacokinetics Variability of the PD-L1–Targeted Antibody-Drug Conjugate PDL1V (PF-08046054)

Iboi E, Chia YL, Zhang F, Harrold J, Forero-Torres A, Lamba M, Garg A, Stoelli F

Encouraging Antitumor Activity of PDL1V (PF-08046054) Monotherapy, an ADC Targeting PD-L1, Correlates with Antigen Expression in Patients with NSCLC

Oliva M, Dowlati A, Desai A, Kotecki N, Saleh R, Sukari A, Burkitt K, Steeghs N, Garralda Cabanas E, Zivi A, Laux D, Gillison M, Patniak A, Minchom A, Ochsenreither S, Ouali K, Le Tourneau C, Gupta S, Zhang R, Fontana E

Maura Gillison, Marc Oliva, Chrisophe Le Tourneau, Ramy Saleh, Amita Patnaik, Jonathan W. Riess, Neeltje Steeghs, Justin Call, Afshin Dowlati, Elisa Fontana, Elena Garralda Cabanas, Arjun Oberoi, Nuria Kotecki, Anna Minchom, Sebastian Ochsenreither, Kaissa Ouali, Anna Spreafico, Andrea Zivi, Shivani Gupta, Rong Zhang, Lisle Nabell

Interim Results of PDL1V (PF-08046054), a Vedotin-Based ADC Targeting PD-L1, in Patients With NSCLC in a Phase 1 Trial

Fontana E, Desai A, Kotecki N, Sàbat P, Le Tourneau C, Steeghs N, Patnaik A, Riess J, Dowlati A, Call J, Garralda Cabanas E, Gillison M, Minchom A, Ochsenreither S, Ouali K, Spreafico A, Zivi A, Gupta S, Zhang R, Saleh R

Interim Results of a Phase 1 Study of SGN-PDL1V (PF-08046054) in Patients with PDL1-Expressing Solid Tumors

Oliva M, Ochsenreither S, Le Tourneau C, Champiat S, Saleh R, Burkitt K, Nabell L, Steeghs N, Spreafico A, Minchom A, Patniak A, Call J, Fontana E, Kotecki N, Cabanas G, Zivi A, Riess JW, Gupta S, Zhang R, Gillison M